- Reaction score
- 320
This is the first study showing that bortezomib reduces DKK‐1 and RANKL serum levels, leading to the normalisation of bone remodelling in relapsed myeloma.
There are recent reports that bortezomib may increase serum alkaline phosphatase activity, which is consistent with enhanced osteoblast function
Dickkopf‐1 (DKK‐1) protein is an inhibitor of Wntsignalling that participates in osteoblast dysfunction in MM
The administration of bortezomib produced a significant reduction of DKK‐1, sRANKL, CTX and TRACP‐5b after 4 cycles, which was still seen after eight cycles of treatment.
There was no correlation between changes of DKK‐1 with changes of other molecules studied. However, responders (CR + PR) tended to have lower initial levels of DKK‐1 compared with non‐responders
There are recent reports that bortezomib may increase serum alkaline phosphatase activity, which is consistent with enhanced osteoblast function
Dickkopf‐1 (DKK‐1) protein is an inhibitor of Wntsignalling that participates in osteoblast dysfunction in MM
The administration of bortezomib produced a significant reduction of DKK‐1, sRANKL, CTX and TRACP‐5b after 4 cycles, which was still seen after eight cycles of treatment.
There was no correlation between changes of DKK‐1 with changes of other molecules studied. However, responders (CR + PR) tended to have lower initial levels of DKK‐1 compared with non‐responders